技術摘要（英）
Neutrophils play a crucial role in various inflammatory diseases including acute respiratory syndrome (ARDS). The chemotaxis and activation of neutrophils are regulated by formyl peptide receptor I (FPR1). Overactivated function of neutrophil can be relieved by FPR1 antagonist in treatment of inflammatory disease. By treatment of DCB’s FPR1 antagonists, inflammatory mediator release of neutrophil was reduced in in vitro studies and neutrophil infiltration was decreased in acute lung injury model as well. Similar efficacy was revealed in DCB’s FPR1 antagonist treatment compared with Elaspol, a neutrophilic elastase inhibitor, at 1/100th of the dosage. The provisional structure patent of DCB’s FPR1 antagonist have been applied.